A Number of High Value Drugs due to Come off Patent in the USA and Europe over the next few years are Injectable.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c30418) has announced the addition of Injectable in·ject·a·ble adj. Capable of being injected. Used of a drug. n. A drug or medicine that can be injected. Generic Drugs generic drug, a drug sold or prescribed under the nonproprietary name of its active ingredients or under a generally descriptive name rather than under a brand or trade name. : Prospects and Opportunities to 2010 to their offering. A number of high value drugs due to come off patent in the USA and Europe over the next few years are injectable. These include drugs to treat cancer, venous thrombosis thrombosis (thrŏmbō`sĭs), obstruction of an artery or vein by a blood clot (thrombus). Arterial thrombosis is generally more serious because the supply of oxygen and nutrition to an area of the body is halted. , gastrointestinal disorders Noun 1. gastrointestinal disorder - illness caused by poisonous or contaminated food food poisoning illness, sickness, unwellness, malady - impairment of normal physiological function affecting part or all of an organism and hospital acquired infections. Alongside these and falling in the same therapeutic categories are drugs that have come off patent in the USA since 2004 and have attracted generic competition, such as cancer therapies carboplatin and paclitaxel paclitaxel /pac·li·tax·el/ (pak?li-tak´sel) an antineoplastic that promotes and stabilizes polymerization of microtubules, isolated from the Pacific yew tree (Taxus brevifolia); . Generic companies are also beginning to take an interest in some of the older high value biopharmaceuticals, including erythropoietin erythropoietin /eryth·ro·poi·e·tin/ (-poi´e-tin) a glycoprotein hormone secreted by the kidney in the adult and by the liver in the fetus, which acts on stem cells of the bone marrow to stimulate red blood cell production , filgrastim, recombinant insulin, somatropin and interferon interferon (ĭn'tərfēr`ŏn), any of a group of proteins produced by cells in the body in response to an attack by a virus. A cell infected by a virus releases minute amounts of interferons, which attach themselves to neighboring cells, . If regulatory hurdles can be overcome, the potential rewards for generic companies in biosimilar products are huge. While the first approval of a biosimilar product has yet to happen in either the US or the EU, the new EMEA (Europe, Middle East, Africa) Refers to that region of the world. For example, one might see products packaged differently for the UK, EMEA and Asia Pacific markets. guidelines can be seen as a step in the right direction. The traditional view of generic drugs is that they offer a cheap alternative to their branded equivalents. Cost has been an important factor in their development, particularly for oral drugs that are relatively cheap to produce and can be introduced to that market at a fraction of the price of the original drug. Generic companies are, however, beginning to look for higher profit margins and injectable drugs potentially offer such opportunities. Combined sales of the non-biological injectables included in this study will be in the region of US$16.5 billion in 2005, of which around US$5.5 billion will lose patent protection in the USA by 2010. The proprietary biopharmaceuticals that are believed most likely to become available as generics once the legal hurdles to registration have been overcome, currently have combined sales in the region of US$25.4 billion. This report will provide industry planners, commercial developers and the investment community with a thorough review of the operating landscape for generic injectables over the next 5 years. The report is packed with primary source information and market forecasts, and takes a balanced view of the players and products that will shape this high value market sector. Providing: --Product/Market Forecast by value 2005/2010 --Market Context --Competitive Evaluation --Company Reviews --Analysis of significant litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. --Patent expiry opportunities to 2014 Companies mentioned in the report: --American Pharmaceutical Partners --Amphastar --Apotex --Baxter Healthcare --Bedford Laboratories --Hospira --Mayne Pharma --Orchid --Paddock Laboratories --Sandoz --Spectrum --Pharmachemie (Teva) --Sicor (Teva) For more information visit http://www.researchandmarkets.com/reports/c30418 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion